Pune, India, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The global bendamustin market size is projected to experience dynamic expansion in the upcoming years owing to the increasing prevalence of chronic lymphocytic leukemia across the world, finds Fortune Business Insights in its report, titled “Bendamustin Market, 2021-2028”.
Regional Insights:
Increasing Number of People Affected with Chronic Lymphocytic Leukemia to Boost the North America Market Growth
North America region is projected to witness substantial growth in the bendamustin market share on account of the increasing number of people affected with chronic lymphocytic leukemia in this region.
European region is anticipated to grow speedily in this market due to the surging demand for bendamustin in the countries such as the UK, Germany, Italy, France, and others.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bendamustin-market-103096
Bendamustin is used to treat Chronic Lymphocytic Leukemia (CLL), a type of cancer of the white blood cells. There has been an increasing prevalence of chronic lymphocytic leukemia among the people possessing the symptoms such as swollen lymph nodes, fatigue, and easy bruising. This is an important factor augmenting the growth of this market during the forecast period. For instance, as per the report released by the National Cancer Institute, there were approximately 186,422 people living with chronic lymphocytic leukemia in the United States in the year 2017. However, there are certain side-effects associated with bendamustin, which is projected to hamper the growth of this market.
The COVID-19 pandemic has had no negative impact on the bendamustin market growth as this type of drug is available in all the major hospitals and retail pharmacies during this pandemic, which is one of the driving factors responsible for this market’s growth.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/bendamustin-market-103096
Market Segmentation:
On the basis of dosage form, this market is classified into liquid, 100-mg injection, 25mg injection, and lyophilized. Based on application, the market is divided into chronic lymphocytic leukemia, non-hodgkin’s lymphoma, and multiple myeloma. By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and others. In terms of geography, the market is clubbed into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Quick Buy - Bendamustin Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/103096
Highlights/Summary:
This research report offers an in-depth study of the driving factors, restraints and trends influencing the growth of the market. In addition, this report offers a detailed evaluation of the market segments and regional developments in the market. Further, this report also incorporates a comprehensive analysis of the strategies adopted by market players to strengthen their position.
Drivers/Restraints:
Increasing Healthcare Facilities by the Government across the World to Fuel the Market
In recent years, there has been a significant increase in the healthcare facilities by the governments of several countries. Further, there are many initiatives being undertaken by the government in order to improve the healthcare facilities in the developing as well as developed nations. Thus, this is a crucial factor contributing to the growth of this market.
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/bendamustin-market-103096
Competitive Landscape:
Technological Advancements in Healthcare Industry to Animate Competition
The leading companies in the bendamustin market are focusing on the adoption of advanced technologies in order to improve the healthcare facilities across the world. This has resulted in the increasing competition among key companies which will enable them to widen their business operations and strengthen their market position.
Industry Development:
May 2018: Eagle Pharmaceuticals, Inc. received the USFDA approval for its ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml for the treatment of patients with chronic lymphocytic leukemia and Non-Hodgkin’s lymphoma.
Key Players Covered in the Bendamustin Market Report:
Teva Pharmaceutical Industries Ltd., Eisai Co., Ltd., Mundipharma International., Mylan N.V., NATCO Pharma Limited., Emcure Pharmaceuticals Ltd, Eagle Pharmaceuticals, Inc.
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
